Nilutamidum [Latin]

Nilutamidum [Latin] - General Information

Nilutamidum [Latin] is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamidum [Latin] is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamidum [Latin] blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

Pharmacology of Nilutamidum [Latin]

Nilutamidum [Latin] is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamidum [Latin] is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamidum [Latin] blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

Nilutamidum [Latin] for patients

Patients should be informed that NILANDRON tablets should be started on the day of, or on the day after, surgical castration. They should also be informed that they should not interrupt their dosing of NILANDRON or stop taking this medication without consulting their physician.
Because of the possibility of interstitial pneumonitis, patients should also be told to report immediately any dyspnea or aggravation of pre-existing dyspnea.

Because of the possibility of hepatitis, patients should be told to consult with their physician should nausea, vomiting, abdominal pain, or jaundice occur.
Because of the possibility of an intolerance to alcohol (facial flushes, malaise, hypotension) following ingestion of NILANDRON, it is recommended that intake of alcoholic beverages be avoided by patients who experience this reaction. This effect has been reported in about 5% of patients treated with NILANDRON.

In clinical trials, 13% to 57% of patients receiving NILANDRON reported a delay in adaptation to dark, ranging from seconds to a few minutes, when passing from a lighted area to a dark area. This effect sometimes does not abate as drug treatment is continued. Patients who experience this effect should be cautioned about driving at night or through tunnels. This effect can be alleviated by the wearing of tinted glasses.

Nilutamidum [Latin] Interactions

In vitro, nilutamide has been shown to inhibit the activity of liver cytochrome P-450 isoenzymes and therefore, may reduce the metabolism of compounds requiring these systems.
Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, phenytoin, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level. The dosage of these drugs or others with a similar metabolism may need to be modified if they are administered concomitantly with nilutamide. For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.

Nilutamidum [Latin] Contraindications

NILANDRON tablets are contraindicated in patients:

• with severe hepatic impairment (baseline hepatic enzymes should be evaluated prior to treatment)
• with severe respiratory insufficiency
• with hypersensitivity to nilutamide or any component of this preparation.

Additional information about Nilutamidum [Latin]

Nilutamidum [Latin] Indication: For use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2)
Mechanism Of Action: Nilutamidum [Latin] competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Nilutamide
Synonyms: Not Available
Drug Category: Androgen Antagonists; Antineoplastic Agents
Drug Type: Small Molecule; Approved

Other Brand Names containing Nilutamide: Anandron; Nilandron; Nilandrone; Nilutamida [Spanish]; Nilutamide [Usan-Ban-Inn]; Nilutamidum [Latin];
Absorption: Rapidly and completely absorbed, yielding high and persistent plasma concentrations.
Toxicity (Overdose): Symptoms of overdose include dizziness, general discomfort, headache, nausea, and vomiting.
Protein Binding: Not Available
Biotransformation: The results of a human metabolism study using 14C-radiolabelled tablets show that nilutamide is extensively metabolized and less than 2% of the drug is excreted unchanged in urine after 5 days.
Half Life: 38.0-59.1 hours
Dosage Forms of Nilutamidum [Latin]: Tablet Oral
Chemical IUPAC Name: 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
Chemical Formula: C12H10F3N3O4
Nilutamide on Wikipedia: https://en.wikipedia.org/wiki/Nilutamide
Organisms Affected: Humans and other mammals